Pressure Injury PreventionNCT07852897
Evaluation of Commercially Available Heel Pads for the Prevention of Pressure Ulcers: An Observational Study of Incidence and Usability in Adult Surgical Patients.
An observational study of Pressure Injury Prevention, run by Trulife at 1 site in Ireland.
Trial summary
This study will evaluate the incidence of heel pressure ulcers in adult patients undergoing elective surgery while using the Oasis Elite Heel Pad (EL130) as part of routine pressure ulcer prevention. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pressure Injury Prevention
- What is being tested?
- Oasis Elite Heel Pad (EL130)
- Type of treatment
- Medical device
- How many people
- 35 participants
- Where
- 1 siteIreland
- Study dates
- 9 Jun 2026to 9 Jun 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Phase 1 will include a convenience sample of adult patients undergoing elective surgery at Connolly Hospital Dublin who are planned to use the Oasis Elite Heel Pad (EL130) as part of routine intraoperative pressure ulcer prevention. Participants will be followed from the preoperative period through 72 hours postoperatively. Phase 2 will include approximately 15 multidisciplinary surgical theatre staff who were involved in the surgery of Phase 1 participants and who used the heel pad intraoperatively. Staff who volunteer to participate will complete a semi-structured interview about the usability, acceptability, and perceived value of the heel pad.
Who may be able to join
- Adult patients aged 18 years or older
- Admitted preoperatively for elective surgery
- Planned surgery duration of at least 1 hour
- Anticipated/planned length of hospital stay of 3 days
- Able to provide informed consent to participate
- Intraoperative use of the Oasis Elite Heel Pad (EL130) planned as part of routine pressure ulcer prevention
Who cannot join
- Undergoing emergency surgery
- Planned surgical position that does not require heel pads intraoperatively (e.g., prone position)
- Anticipated/planned length of hospital stay of less than 3 days at study enrolment
- Visual pressure ulcers present on both heels at baseline
- Unable to provide informed consent
- Oasis Elite Heel Pads (EL130) not being used intraoperatively
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study will evaluate the incidence of heel pressure ulcers in adult patients undergoing elective surgery while using the Oasis Elite Heel Pad (EL130) as part of routine pressure ulcer prevention. The study will also explore the usability, acceptability, and perceived value of the heel pad among multidisciplinary surgical theatre staff.
The study has two phases. Phase 1 is a prospective observational study involving approximately 35 adult surgical patients. The use of the heel pad is part of standard care and participation in the study will not alter participants' routine clinical care. Pressure ulcer development at both heels will be assessed using visual skin assessment (VSA) and subepidermal moisture (SEM) assessment with the Provizio® SEM Scanner. Assessments will be performed before surgery, hourly during surgery, and during postoperative follow-up for up to 72 hours.
Read more
The primary outcome of Phase 1 is the incidence of heel pressure ulcers detected by SEM assessment and VSA. The study will also examine changes in SEM measurements during surgery and the time to development of a heel pressure ulcer during the study follow-up period.
Phase 2 is a qualitative usability study involving approximately 15 multidisciplinary surgical theatre staff who have used the heel pads during the Phase 1 study period. Participants will take part in individual semi-structured interviews exploring the usability, acceptability, and perceived value of the heel pads for intraoperative pressure ulcer prevention.
Read the detailed description
Pressure ulcers are areas of tissue damage associated with pressure and shear forces and are an important potential complication for patients undergoing surgery. Patients undergoing surgical procedures may be at increased risk because they can remain immobile in one position for prolonged periods and are unable to respond to discomfort associated with pressure and shear while undergoing surgery.
The aim of this study is to determine the incidence of pressure ulcers at the heels among adult surgical inpatients using the Oasis Elite Heel Pad (EL130), with pressure ulcer development assessed using both subepidermal moisture (SEM) assessment and visual skin assessment (VSA). The study will also explore the usability, acceptability, and perceived value of the heel pad among multidisciplinary surgical theatre staff.
This is a single-site, multiphase study consisting of two phases.
Phase 1: Prospective observational study
Approximately 35 adult patients admitted for elective surgery will participate in Phase 1. Eligible participants will be adults aged 18 years or older who are admitted preoperatively for elective surgery, have a planned surgery duration of at least one hour, have an anticipated length of hospital stay of approximately three days, and are planned to use the Oasis Elite Heel Pads (EL130) as part of routine intraoperative pressure ulcer prevention.
The study does not require a change to standard clinical care. The Oasis Elite Heel Pads are already used at the study site for routine pressure ulcer prevention. Research assessments conducted during the study are additional to routine clinical assessments and do not direct or influence clinical care decisions.
Participants will undergo assessment of both heels using VSA and SEM assessment with the Provizio® SEM Scanner. A baseline assessment will be performed before surgery. Assessments will then be performed hourly during the intraoperative period and during postoperative follow-up for up to 72 hours.
VSA will assess the appearance of the skin at each heel and pressure ulcers will be classified using the NPUAP/EPUAP/PPPIA pressure ulcer classification system. SEM assessment is a non-invasive assessment performed using the Provizio® SEM Scanner. The scanner measures subepidermal moisture associated with inflammatory changes in tissue. Four measurements are collected from each heel and used to generate a SEM delta value.
The primary outcome of Phase 1 is the incidence of SEM- and VSA-detected pressure ulcers at the heels among adult surgical inpatients using the heel pad. A SEM-detected pressure ulcer will be defined as two sustained elevated SEM measurements over two consecutive days at the same anatomical location, with a SEM delta value of 0.6 or greater, among participants who had a normal SEM reading preoperatively. A VSA-detected pressure ulcer will be defined according to the NPUAP/EPUAP/PPPIA pressure ulcer classification system.
Secondary outcomes include observation of hourly SEM delta values during surgery while participants are using the heel pad and the length of time to development of a pressure ulcer at the heels during the intraoperative and postoperative study period.
Relevant demographic and surgical information will also be collected to describe the study population and provide context for the study findings. This includes age, sex, skin tone, surgery type, position during surgery, time spent in surgery, and the type of heel pad used at the heels intraoperatively.
Phase 2: Qualitative usability study
Phase 2 will explore the usability, acceptability, and perceived value of the Oasis Elite Heel Pad among multidisciplinary surgical theatre staff involved in the care of participants recruited during Phase 1.
Approximately 15 multidisciplinary surgical theatre staff who have used the heel pad intraoperatively during the Phase 1 data collection period will be invited to participate. Recruitment will continue until sufficient qualitative data have been obtained.
Following informed consent, staff participants will take part in an individual semi-structured interview lasting no more than approximately 30 minutes. Interviews will explore staff perceptions of the usability, acceptability, and perceived value of the heel pad for intraoperative pressure ulcer prevention, including usability issues and contextual barriers or facilitators that may influence its adoption and continued use in clinical practice.
Interview transcripts will be analysed using thematic analysis to identify themes relating to staff experiences and perceptions of the heel pad and potential opportunities for design or workflow improvements.
The study will be conducted at Connolly Hospital Dublin. The overall study, including preparation, data collection, analysis, and write-up, is planned to be completed within approximately 12 months.
- Conditions
- Pressure Injury Prevention
- Being tested
- Oasis Elite Heel Pad (EL130)
- Keywords
- Pressure Injury Prevention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oasis Elite Heel Pad (EL130)Device
The Oasis Elite Heel Pad (EL130) is a reusable, non-sterile heel pad used as part of routine intraoperative pressure ulcer prevention. The device supports the Achilles tendon and distributes pressure away from the heel across a larger surface area. Use of the heel pad is part of standard care at the study site and is not assigned by the study investigators. The study will observe the incidence of heel pressure ulcers among surgical patients using the device.
| Study group | Role | What they receive |
|---|---|---|
| Adult surgical patients using Oasis Elite Heel Pads | Adult patients undergoing elective surgery who use the Oasis Elite Heel Pad (EL130) as part of routine intraoperative pressure ulcer prevention. Participants will undergo visual skin assessment (VSA) and subepidermal moisture (SEM) assessment of both heels before surgery, hourly during surgery, and during postoperative follow-up for up to 72 hours. Use of the heel pad is part of standard care at the study site and is not assigned as a research intervention. Receives: Device: Oasis Elite Heel Pad (EL130) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of heel pressure ulcers detected by SEM assessment and visual skin assessment.
Incidence of heel pressure ulcers (PUs) detected using subepidermal moisture (SEM) assessment and visual skin assessment (VSA). Incidence will be calculated as the number of new PUs observed during the study period divided by the number of participants at risk at baseline, multiplied by 100. A SEM-detected PU is defined as two sustained elevated SEM measurements (delta ≥0.6) over two consecutive days at the same anatomical location among participants with a normal SEM reading preoperatively. A VSA-detected PU is defined as a grade 1-6 PU according to the NPUAP/EPUAP/PPPIA classification system.
Measured: From preoperative baseline through 72 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study start9 Jun 2026
- Primary completion9 Dec 2026 (estimated)
- Study completion9 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pressure Injury PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Trulife
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Royal College of Surgeons, Ireland
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07852897
- Sponsor's protocol ID
- TruE130
- Status last verified
- Sep 2026
- First submitted
- 23 Sep 2026
- Last updated
- 1 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: Individual participant data (IPD) are not planned to be shared with other researchers. Participant-level study data will be stored securely with access restricted to authorised members of the research team and relevant authorised personnel, in accordance with the study protocol and applicable data protection requirements. Study findings will be disseminated in aggregate form.